Parameter
| Biomarker | HER2 (human epidermal growth factor receptor 2) | Full name | Human epidermal growth factor receptor 2 (ERBB2) | Molecular Type | Protein/nucleic acid (DNA/RNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and prediction | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Tumor tissues (IHC, FISH, NGS), circulating tumor DNA (ctDNA, NGS) | ||
| Pathobiological Mechanisms | Tyrosine kinase receptor ERBB2 gene encoding across a cell membrane, stomach cancer is about 10% - 20% HER2 gene amplification or protein expression, by activating MAPK, PI3K/Akt pathway drive unlimited proliferation of tumor cells, inhibit apoptosis, is the core of the HER2 targeting treatment targets | ||||
| Clinical Availability Status | Clinical availability (targeted therapy screening) : the guideline-recommended first-line detection of gastric cancer, HER2-positive patients can use targeted drugs such as trastuzumab | ||||
| Notes and Dynamics | Tumor heterogeneity should be paid attention to in the detection of precise targeted therapy for gastric cancer. Combined chemotherapy can significantly prolong the survival of patients with HER2-positive advanced gastric cancer. The mechanisms of drug resistance (such as HER2 mutation and MET amplification) are current research hotspots | ||||